Patents by Inventor Iris Tranthuyngan TO

Iris Tranthuyngan TO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
    Patent number: 12291575
    Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: May 6, 2025
    Assignee: Genentech, Inc.
    Inventors: Carol Elaine O'Hear, Yasuhiro Oki, Iris Tranthuyngan To
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES IN ELDERLY PATIENTS
    Publication number: 20230416391
    Abstract: The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL). More specifically, the invention pertains to the treatment of subjects having an R/R NHL by intravenous administration of mosunetuzumab.
    Type: Application
    Filed: May 31, 2023
    Publication date: December 28, 2023
    Inventors: Huang HUANG, Carol Elaine O'HEAR, Iris Tranthuyngan TO, Michael Ching-sun WEI, Shen YIN
  • METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN
    Publication number: 20220411528
    Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 29, 2022
    Inventors: Carol Elaine O'HEAR, Yasuhiro OKI, Iris Tranthuyngan TO
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES
    Publication number: 20220153842
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Stephen James SIMKO, III, Iris Tranthuyngan TO, Klara TOTPAL, Hong WANG, Michael C. WEI, Shen YIN, Brendan Christian BENDER, Xi CHEN, Yu-Waye CHU, Maria HRISTOPOULOS